ROKU - Jim Cramer: These Airline Stocks 'Trade Wildly' Edwards Lifesciences 'At The Right Level To Buy' | Benzinga
On CNBC's “Mad Money Lightning Round,” Jim Cramer said the new product line of Edwards Lifesciences Corporation (NYSE:EW) is “pulling back here.” “That may be the right level to buy it. They are doing very well now,” he added.
On April 25, Edwards Lifesciences posted better-than-expected results for its first quarter. The company said it sees FY24 adjusted EPS of $2.70 to $2.80 on revenue of $6.3 billion to $6.6 billion.
When asked about Freeport-McMoRan (NYSE:FCX), he said, “I want it to come in first, it's been straight up. I do not like parabolic moves.”
On April 23, Freeport-McMoRan reported first-quarter FY24 results. Revenue stood at $6.32 billion, beating the consensus of $5.66 billion. Adjusted ...